Drug Interactions between folic acid and Renagel
This report displays the potential drug interactions for the following 2 drugs:
- folic acid
- Renagel (sevelamer)
Interactions between your drugs
No interactions were found between folic acid and Renagel. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
folic acid
A total of 35 drugs are known to interact with folic acid.
- Folic acid is in the drug class vitamins.
- Folic acid is used to treat the following conditions:
Renagel
A total of 43 drugs are known to interact with Renagel.
- Renagel is in the drug class phosphate binders.
- Renagel is used to treat Hyperphosphatemia of Renal Failure.
Drug and food interactions
folic acid food
Applies to: folic acid
MONITOR: Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics. Excessive alcohol consumption may lead to folate deficiency.
MANAGEMENT: Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
- Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
- (2017) "Product Information. Folic Acid (folic acid)." Method Pharmaceuticals, LLC
sevelamer food
Applies to: Renagel (sevelamer)
ADJUST DOSING INTERVAL: Sevelamer may decrease the oral bioavailability of concomitantly administered drugs. While clinical data are lacking for most drugs, the intestinal absorption of some may be impaired due to sevelamer's binding capabilities.
MANAGEMENT: As a precaution, drugs that can be adversely affected by alterations in blood levels should be administered 1 hour before or 3 hours after sevelamer.
References
- (2001) "Product Information. Renagel (sevelamer)." Genzyme Corporation
- (2002) "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.